Teleflex Incorporated Common Stock (TFX)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for consistent earning power, high returns on capital, and a price that leaves a margin of safety. Teleflex sells single-use devices for critical care and surgery, which can be a decent niche. But the reported record is uneven. In fiscal 2025, the year ended 2025-12-31, revenue was $2.0B, yet net income was -$905.6M and diluted EPS was -$20.25. That followed net income of $69.7M in fiscal 2024 and $356.3M in fiscal 2023. The fiscal Q4 2025 quarter, ended 2025-12-31, alone lost $714.3M. The recent fiscal Q2 2026 quarter, ended 2026-06-30, showed revenue of $570.3M and net income of $99.7M, so a turnaround may be forming. Still, trailing EPS is -$0.54, ROE is -0.70%, ROCE is 1.75%, and the P/E is -230.44. Debt to equity is 1.01 and the Altman Z-score is 1.80, both cautionary. On the positive side, trailing free cash flow is $327.1M, a 6.2% FCF yield, and the dividend yield is 1.09%. At $124.44 on 2026-10-13, P/B is 1.82 and EV/EBITDA is 45.0. FairStock's Lynch category is TURNAROUND, caused by a loss in the latest year after earlier profits. I would want proof that the latest quarterly profit is durable and that debt can be reduced before treating this as a Graham-style bargain.

In plain English: Teleflex makes single-use medical devices used in critical care and surgery. The business is mixed: it lost money in fiscal 2025, but it earned a profit in the latest reported quarter and generates cash. At $124.44 on 2026-10-13, the shares look expensive relative to weak trailing earnings and low returns, so the price seems fair-to-rich unless the recent profit lasts.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-28) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer